



CAPRISA

CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

Newsletter

Nov/Dec 2024 Volume 24 Issue 8

Advances in HIV-1 vaccine:

Insights from a Phase 1/2a trial

In this Issue

On page 1, we feature an article on HIV-1 vaccine development published in *JAIDS*.

We report on Prof Kogie Naidoo's appointment to the TB Transformative Science Group Vice Chair.

On page 3, we feature the Op-Ed in Spotlight and an event co-hosted by UKZN, CAPRISA and AHRI to commemorate World AIDS Day in 2024.

On page 4, we congratulate CAPRISA senior scientist, Prof Rubeshan Perumal, on achieving Associate Professorship by UKZN and receiving UKZN's Vice-Chancellor's Research Award.

We feature the new appointments of Heads of Departments at CAPRISA on page 5.

On page 6, we highlight the participation of CAPRISA staff and students at the Union World Conference on Lung Health in Bali, Indonesia.

On page 7, we report on Prof Quarraisha's participation in the STS Forum in Kyoto and the CLIENT Conference in Berlin.

CONTACT DETAILS

CAPRISA
Doris Duke Medical
Research Institute (DDMRI)
2nd Floor
University of KwaZulu-Natal
Private Bag X7, Congella 4013
South Africa



T: +27-31-260 4555
F: +27-31-260 4566

E-mail: caprisa@caprisa.org

www.caprisa.org.za

A recent study by Garrett et al. published in the *Journal of Acquired Immune Deficiency Syndromes* revealed encouraging outcomes from a trial on the safety and immunogenicity of a novel HIV-1 vaccine regimen, offering valuable direction for future HIV prevention efforts.

Conducted in South Africa and the U.S., the HIV Vaccine Trials Network 108 randomized, placebo-controlled Phase 1/2a trial evaluated a combination of a DNA vaccine (DNA-HIV-PT123) with bivalent subtype C gp120 proteins (TV1.C and 1086.C), adjuvanted with either MF59 or AS01B. The trial explored prime-boost and co-administration strategies, assessing safety, immune responses, and response durability over a 12-month period.

The vaccine regimen demonstrated a favourable safety profile, with mild to moderate adverse events. Notably, participants receiving AS01B-adjuvanted regimens reported slightly higher reac-

togenicity than those receiving MF59, though these events remained manageable.


The study revealed robust immune responses across all regimens, with over 89% of participants achieving high IgG antibody response rates. AS01B-adjuvanted regimens outperformed their MF59 counterparts, showing near 100% response rates and eliciting stronger antibody and CD4+ T cell responses. Interestingly, low-dose AS01B protein regimens delivered immune responses comparable or superior to high-dose regimens, emphasizing their potential as an optimized vaccine strategy. Furthermore, immune responses remained durable, with high magnitudes sustained six months after the final vaccination.

In conclusion, the findings highlight AS01B's superior adjuvant potential in generating robust and long-lasting immunity and validate the potential of DNA/protein vaccine regimens employing prime-boost or co-administration strategies to balance efficacy and safety, particularly with low protein doses.

Given the prevalence of subtype C HIV in regions like Southern Africa, these results hold particular promise for vaccine strategies tailored to high-burden areas.

For further reading see: *J Acquir Immune Defic Syndr* 2024; 96(4):350-360. <https://doi.org/10.1097/QAI.0000000000003438>

Figure: The CD4+ T cell response rates and magnitude 2 weeks and 6 months after final immunization for vaccine-matched antigens, as measured by intracellular cytokine staining.





Quarraisha Abdool Karim at 2024 VinFuture Prize Award Ceremony

Professor Quarraisha Abdool Karim attended the 2024 VinFuture Prize Award Ceremony Week, which took place in Hanoi, Vietnam, from 4–7 December, where she met with the Prime Minister of Vietnam, his Excellency Pham Minh Chinh, and participated in media engagement with the local press as well as meetings with the Prize Council.

Photo: Front row (L-R): Prof Quarraisha Abdool Karim; his Excellency Pham Minh Chinh, Prime Minister of Vietnam; Prof Firdausi Qadri, ICDDR, Univ of Bangladesh, 2024 Vinfuture (VF) Prize winner for Developing Countries. 2nd row (L-R): Prof Thuc-Quyên, Chair, VinFuture PSC/UC Santa Barbara; Mr Jen-Hsun Huang, CEO and Founder, Nvidia, 2024 VF Grand Prize winner; Prof Er-mias Kebreab, VF PSC/UC Davis. 3rd Row: Prof Carl June, CAR T Cell Therapy pioneer, 2024 VF Emerging Technology Prize



Prof Kogie Naidoo appointed to the TB Transformative Science Group Vice Chair

CAPRISA's Deputy Director, Prof Kogie Naidoo, has been appointed Vice Chair of the Tuberculosis Transformative Science Group (TB TSG). The ACTG TB TSG is responsible for the development, implementation, and oversight of the ACTG research agenda related to the treatment and prevention of TB with and without HIV co-infection. The TB TSG aims to develop



shorter, safer treatment regimens for drug-susceptible and resistant TB; identify optimal TB preventive therapy for drug-susceptible latent TB infection and household contacts exposed to multi-DR-TB; identify regimens that treat TB meningitis and isoniazid-mono-resistant TB; and optimize TB treatment and prevention for people with TB/HIV co-infection.

Engaging with global leaders at the WHO, the Africa CDC and the World Science Forum

This November, Professor Salim Abdool Karim engaged in meetings with the Director-General of the World Health Organization, Dr Tedros Adhanom Ghebreyesus, in Geneva, Switzerland, and with leaders of the Africa CDC in Addis Ababa, Ethiopia.

Prof Abdool Karim also moderated a panel session at the World Science Forum in Budapest on 'How can policy address health impacts of climate change? Science, uncertainty and risk'.





World AIDS Day

The 2024 World AIDS Day Panel Discussion, co-hosted by CAPRISA, the University of KwaZulu-Natal (UKZN), the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), and the Africa Health Research Institute (AHRI), took place at the Nelson R Mandela School of Medicine Campus, Durban, on 3 December. The event was themed “equal rights, equal care”.

The discussion was facilitated and chaired by Mr Siyabonga Nzimande, a Public Health Subject Expert and Head of the Health Unit at Enhancing Care Foundation. Panellists of the discussion included Mr Patrick Mdletshe (Head of Community Programmes, CAPRISA), Prof Thumbi Ndung'u (Programme Director, SANTHE; Director for Basic and Translational Science, AHRI), Dr Nokukhanya Msomi (Head of Virology, UKZN), Prof Limakatso Lebina (Director for Clinical Trials, AHRI), and Ms Thobeka Bridget Mzimela (recent graduate with a Bachelor of Social Science in Criminology and Psychology, UKZN).



Mr Mdletshe initiated the panel discussion by highlighting the theme of the event, reiterating that “no one should be left behind”. He also explained the importance of closing the generation gap in an effort to educate kids about pre-exposure prophylaxis (PrEP) by their parents. He also discussed that just as women need to have choices in terms of shoes and clothing, they need to be given several options for PrEP.

Prof Ndung'u highlighted South Africa's progress in mounting a rights-based approach, but that we have not reached people that need to be reached regarding the 90-90-90 goals. He emphasised the fact that we are seeing mother-to-child transfer in an era where children should not be acquiring HIV, and stressed the need for social interventions to reach those people who only come to the clinic later than necessary.

Prof Kogie Naidoo (CAPRISA) highlighted the need for community-driven HIV prevention and treatment, emphasizing researcher-community collaboration to tackle ongoing challenges in the fight against HIV/AIDS.



Professor Salim Abdool Karim (Director, CAPRISA) and Dr Nikita Devnarain (Research Associate, CAPRISA) published an Op-Ed in Spotlight ahead of World AIDS Day 2024, arguing that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention, like Lenacapavir. “The AIDS control programme in our country will need to develop innovative ways of getting this injection to those at the highest risk of HIV to impact the cycle of HIV transmission ... South Africa has gotten tantalisingly close to the 2025 treatment targets. But it still has a long way to go to achieve the 2030 SDG goal for AIDS.”



South Africa's AIDS response: Progress, challenges, and opportunities



For more reading see here: <https://www.spotlightnsp.co.za/2024/11/28/south-africas-aids-response-progress-challenges-and-opportunities/>



CAPRISA senior scientist, Professor Rubeshan Perumal, honoured by the University of KwaZulu-Natal

Prof Rubeshan Perumal, specialist pulmonologist and senior scientist, has recently been appointed Associate Professor of Clinical Medicine at the University of KwaZulu-Natal. This appointment at age 37 reflects Prof Perumal's diligence in advancing the academic mission through clinical excellence, innovative research, scientific leadership, dedicated teaching, and active University citizenship.

In addition, Prof Perumal was recently named the 2024 recipient of the UKZN Vice Chancellor's Research Award, recognising exceptional contributions to research alongside a sustained scholarship record and celebrating scholars whose work exemplifies the highest standards of innovation, impact, and academic excellence.



Photo above (L-R): Dr Mark Hay, UKZN council member; Prof Rubeshan Perumal

At the recent Global Virus Network (GVN) Scientific Meeting, co-hosted by CAPRISA in October 2024, Prof Perumal was awarded the GVN Action Award recognizing his exceptional efforts and accomplishments as co-chair of the GVN Long COVID Action Committee.

Prof Perumal's scientific journey began in 2005, during his first year at medical school when he joined CAPRISA as a research placement under the mentorship of Professors Kogie Naidoo, Nesri Padayatchi, and Salim Abdool Karim. He holds postgraduate degrees in Public Health (MPH), Medicine (MMed), and Pulmonology (MPhil) and a PhD which focused on the pharmacokinetic-pharmacodynamic optimisation of tuberculosis treatment. He is a past recipient of the Fogarty International Clinical Research Scholarship and was named a Global Young Physician Leader by the Inter-Academy Partnership. He previously served as a research associate at the Centre for Lung Infection and Immunity at the University of Cape Town. Several awards have enhanced his academic development, including the GlaxoSmithKline/South African Thoracic Society Research Fellowship, the AstraZeneca Global Respiratory Leadership Award for Young Investigators, the Pharmacometrics Africa Training Award in Applied Pharmacokinetics, and the American Thoracic Society International Scholars Award.

Prof Perumal coordinates undergraduate training in Internal Medicine, serves as an external examiner for the medical degree programmes of various national universities, is an examiner of specialist and sub-specialist examinations at the Colleges of Medicine of South Africa, and is a faculty member in the Methods in Epidemiologic, Clinical, and Operational Research (MECOR) course hosted by the American Thoracic Society. He supervises several students at the Masters, PhD, and post-doctoral levels. He leads clinical services in pulmonary infectious diseases and interventional pulmonology at Inkosi Albert Luthuli Central Hospital. He serves as principal investigator (PI) or co-PI on more than 10 clinical trials and cohort studies, encompassing several diagnostic and therapeutic innovations in tuberculosis (including drug-resistant TB) and HIV care

As part of his contribution to clinical and scientific leadership, he serves on the KwaZulu-Natal Drug-Resistant TB Advisory Group, the National TB Think Tank, the Guidelines Writing Committee of the South African Thoracic Society, the Long Covid Task Force of the Global Virus Network, the TB Transformative Science Group of the ACTG, and the editorial board of the Annals of the American Thoracic Society. He has previously served on the Cape Town TB Clinical Outreach Service, the Drug-Resistant TB Review Board of the Western Cape, the National Ministerial Advisory Committee Long Covid Working Group, and as a panellist on the World Health Organisation Working Group on Care Pathways for Long Covid.



"Rubeshan serves as a superb role model for aspirant clinician-scientists aiming to achieve the very highest levels of academic, clinical, and scientific excellence", said Prof Busisiwe Ncama, Deputy Vice-Chancellor of UKZN's College of Health Sciences.



Appointments of new Scientific Research Programme Heads at CAPRISA

The following staff have been appointed as Scientific Research Programme Heads at CAPRISA since November 2024.



Dr Nivashnee Naicker – Head of Vaccine Research.

Dr Naicker (MBChB, MPH) is a medical doctor whose primary areas of research interest are HIV prevention and vaccines, and will head Vaccine Research programmes.



Dr Sharana Mahomed – Head of HIV Pathogenesis Research

Dr Mahomed (MBChB, FC Path, MMed, PhD) is a medical doctor trained as a clinical microbiology specialist pathologist. She is actively involved in diagnosing and managing infectious diseases and will head HIV Pathogenesis programmes.



Prof Derseree Archary – Head of Mucosal Immunology Research

Prof Archary (PhD) is a CAPRISA Senior Scientist, whose primary area of research interest interrogates factors of HIV risk in the female genital tract, and she will head Mucosal Immunology Research programmes, including microbiome research .




Prof Rubeshan Perumal – Head of Treatment Research

Prof Perumal (MBChB, MPH, MMed, MPhil, FCP(SA), Cert Pulmonology (SA), PhD) is a Pulmonologist and CAPRISA Senior Scientist whose primary area of research interest is in HIV and TB treatment, and he will head Treatment Research programmes

HIV vaccine research advancements shine at HVTN 24 southern Africa meeting

Cape Town recently hosted the HIV Vaccine Trials Network (HVTN) 24 Southern Africa Regional Scientific Meeting from 5-7 November, bringing together leading scientists and stakeholders to discuss advancements in HIV vaccine research. The event highlighted the crucial role of the HVTN in the ongoing fight against HIV, particularly in Africa, where the epidemic remains most prevalent.

A standout presentation during the meeting was delivered by Dr Sharana Mahomed, who focused on the HVTN 140/HPTN 101 Phase 1 clinical trial. This trial is evaluating the safety and pharmacokinetics of novel antibody combinations as part of ongoing HIV prevention efforts. Dr Mahomed was awarded a Certificate of Excellence for her exceptional scientific communication and her commitment to using people-first language, exemplifying compassionate and impactful dialogue in the field.





Global health at the Union World Conference on Lung Health in Bali, Indonesia

CAPRISA's Prof Kogieleum Naidoo (Deputy Director), Prof Rubeshan Perumal (Head of Treatment Research Programme), Kegaugetswe Pinky Motsomi (TARGET TB Study Coordinator), Kynesha Moopanar (Research Assistant), Dr Darshan Chetty (Research Fellow) and Senamile Ngema (PHD Research Fellow) attended the Union World Conference on Lung Health, held in Bali, Indonesia, from 12-16 November.

The conference aimed to address key issues in TB and respiratory diseases, explore the impact of climate change on lung health, and discuss strategies for post-COVID-19 care. The meeting also focused on advancing digitised adherence technologies, promoting community-driven health interventions, and sharing best practices for combating TB.

Prof Naidoo delivered an oral presentation titled "Epidemiology, Transmission, Diagnosis, and Management of Drug-resistant TB" and participated in a panel discussion exploring knowledge gaps in the diagnosis and management of HIV-associated TB. Naidoo's poster entitled "Effectiveness of the Xpert XDR Assay for Rapid Triage-and-Treatment of DR-TB: Interim results from the TRIAD Study" highlighted that the GeneXpert XDR assay significantly reduces the time-to-appropriate treatment initiation for drug-resistant TB (DR-TB).

Prof Perumal's presentations, entitled "The Individualized M(X) Drug-Resistant TB Treatment Strategy" and "The Impact of Advanced HIV on the TB Burden in Tongaat, KwaZulu-Natal," emphasized the urgent need for integrated strategies to address concurrent challenges of DR-TB and advanced HIV in high-burden communities.

Dr Chetty presented a poster entitled "Longitudinal Changes in Prevalence and Risk Factors for Extensive Lung Disease in People with Drug-Resistant TB", which showed that persistently high rates of extensive lung disease prolong treatment and contribute to the development of post-TB lung disease.

Ms Motsomi presented an oral abstract entitled "Implementing a Community Transmission Study in a TB-Endemic Setting: Lessons Learned from TARGET-TB," highlighting insights from the TARGET-TB study by quantifying losses along the TB diagnostic cascade to understand the implications for community TB transmission.

Ms Moopanar presented a poster entitled "Longitudinal Analysis of Prevalence and Risk Factors of Cavitory Lung Disease in People with Drug-Resistant TB," which showed that cavitory lung disease is highly prevalent and a significant radiographic feature of DR-TB, raising concerns due to its association with higher bacterial loads and an increased risk of onward transmission.

Ms Ngema presented an oral poster, entitled "Detection of Emerging Drug Resistance in Mycobacterium TB Against New Anti-TB Drugs Using TM4::GeNL Reporter Mycobacteriophage", demonstrating the assay's reliability and potential to significantly improve treatment decisions and outcomes for DR-TB patients.

Dr Santhuri Rambaran presented an oral abstract titled "CD4 T cell profiles during TB/HIV co-infection and their associations with TB treatment response and cavitory disease", which evaluated CD4 T cell phenotypes during active TB in patients with recurrent TB with and without HIV co-infection from the Improving Retreatment Success (IMPRESS) trial and assessed their associations with TB treatment response and cavitory disease. In addition, CAPRISA scientists featured as co-authors of several other abstracts.



Photo left: Delegates at conference, including Prof Kogieleum Naidoo (3rd from left); Dr Anushka Naidoo (5th from right); Prof Rubeshan Perumal (4th from right). Photo middle (L-R): Kynesha Moopanar; Prof Kogieleum Naidoo; Dr Darshan Chetty. Photo right: Ms Senamile Ngema.



Global Leaders Unite at Kyoto's STS Forum to Tackle Global Science and Technology Challenges

Professor Quarraisha Abdool Karim participated in the 21st Annual Science and Technology in Society (STS) Forum, held in Kyoto from 6-8 October, which convened academia, politics, and business leaders to address critical global challenges and opportunities in science and technology. Discussions centred on issues such as artificial intelligence, climate change, and global health disparities, focusing on fostering collaboration, equity, and sustainability.

Prof Abdool Karim was a prominent voice at the event, contributing insights during sustainability and global health sessions. She emphasized the transformative potential of science as a universal language to bridge divides and foster inclusivity. Highlighting global issues such as climate change, pandemics, and conflicts, she underscored the disproportionate impact on vulnerable populations in the Global South and the widening inequalities between the Global North and South, and called for equitable access to scientific advancements, advocating for inclusive policies and international collaboration. In the Global Health session, she delivered a powerful message about infectious diseases, stressing that "no one is safe until everyone is safe."



TWAS President attends CLIENT Conference, Berlin

Professor Quarraisha Abdool Karim, participated in the Federal Ministry of Education and Research (BMBF) meeting at the CLIENT Conference 2024, themed 'Research for sustainable innovations' in Berlin, Germany, from 29-29 November as the President of The World Academy of Sciences (TWAS). She delivered the keynote address and participated in a panel discussion at the event, deliberating the future of international research cooperation and promoting sustainable innovations.



Shaping the Future of HIV Care: 2nd SAHCS Long-Acting Treatment and Prevention Conference

Dr Nigel Garrett delivered a standout presentation titled "From Trial to Implementation – Can IMPALA Help Us Jump Across the Gap?" at the 2nd Southern African HIV Clinicians Society (SAHCS) Long-Acting Treatment and Prevention Conference on 29 October, in Sandton, Johannesburg.



Dr Garrett addressed the critical issue of moving long-acting HIV treatments from clinical trials to real-world applications, especially in Africa where healthcare infrastructure can differ from trial conditions. His talk focused on the IMPALA initiative, which aims to bridge this gap by applying implementation science to ensure that long-acting agents are effectively incorporated into everyday HIV care.



CAPRISA staff receive iSpotU awards



Mr Gabriel Vadivelu, a graduate intern under the CAPRISA Clinical Trial Capacity Building Program, received an iSpotU award in recognition of his innovative strategy in developing two tools to minimize site errors when determining ages of consent and when calculating visit dates that coincide with holidays or December closures. These tools have provided more automation, increased efficiency and accuracy, and contributed to better planning and coordination at the site. His innovation has also had a positive impact on the overall study execution, contributing to the success of the study. The meeting objectives included the synergy in STI and HIV prevention research, improving PrEP uptake and strengthening collaboration and promotion of active involvement between HPTN leadership, site leadership, community, and staff.

Ms Sanelisiwe Mkhize, a pharmacist assistant, received an iSpotU award in recognition of her exceptional counselling skills with participants across studies. Sanelisiwe ensures that participants feel comfortable, understand instructions and verify their understanding by actively engaging them in discussions about how they will take their medication or product. This approach truly stood out, as an external study monitor at the Vulindlela site also noted her outstanding performance.

Photo above (L-R): Ms Nonzwakazi Ntombela; Dr Busi Ntsalaze; Mr Gabriel Vadivelu; Prof Kogie Naidoo, eThekweni Clinical Research Site, CAPRISA. Photo below (L-R): Ms Michele Upfold; Ms Sanelisiwe Mkhize; Dr Disebo Potloane, Vulindlela Research Clinical Site, CAPRISA.

Celebrating 22 Years of Dedication: Joyce Nonhlanhla Mchunu Retires from CAPRISA

After 22 years of dedicated service, Joyce Nonhlanhla Mchunu bids farewell to CAPRISA Vulindlela Clinical Research Site as she embarks on her well-deserved retirement. Her journey with CAPRISA is one of inspiration, resilience, and transformation—a testament to the opportunities and growth the organization fosters.

Joyce began her career at CAPRISA as a cleaner. Through her determination and the support of CAPRISA’s management, she was able to further her education and was promoted to the role of a counsellor. Over the years, she served across all CAPRISA studies with distinction, making a lasting impact on the lives of participants and colleagues alike.

Reflecting on her time at CAPRISA, Joyce shared, “CAPRISA changed my life and restored my dignity in both my family and community. Being a part of this organization has been a life-changing experience that I will always treasure.”

Her exceptional commitment has been recognized through the 5-year, 10-year, and 20-year service milestone awards—symbolizing her dedication and invaluable contributions to the organization’s success.

As she steps into retirement, Joyce leaves behind a legacy of hard work, compassion, and professionalism. She expressed her gratitude to CAPRISA management for their unwavering support and the countless opportunities for growth. She also extended her heartfelt thanks to her colleagues, whose camaraderie and collaboration made her journey all the more rewarding.

We thank Joyce for her 22 years of outstanding service and wish her a fulfilling and joyful retirement. CAPRISA will always remember her remarkable contributions and the positive impact she has made on the organization and its mission.





Dr Simone Richardson awarded the Meiring Naudé Medal



The Meiring Naudé Medal in recognition of Outstanding Early Career Contributions to the furtherance of Science was awarded to Dr Simone Richardson. The award is in recognition of her outstanding contributions to the fields of Virology, Immunology and Vaccine Design.

Dr Simone Richardson, Senior Researcher and Medical Scientist (Virology), Witwatersrand University,

and CAPRISA Research Associate, is the recipient of the Meiring Naudé Medal for 2025 for her major contribution to the fields of Virology, Immunology and Vaccine Design. Her work not only advances the frontiers of knowledge but also delivers significant societal benefits as evidenced by the piece in Nature News.

Visits strengthen partnerships



Councillor Vusumuzi Cyril Xaba, Mayor of eThekweni Municipality (*top photo*), visited CAPRISA on 9 December and met with Professors Salim and Quarraisha Abdool Karim.

Executive members of Freya Biosciences, Dr Johan van Hylckama Vlieg (Chief Scientific Officer), Dr Elleke Bosma (Director Microbiome Research) and Dr Kevin DeLong (Director Translation Research), visited CAPRISA over three days from 4-6 December (*bottom photo*). The delegation met with various CAPRISA staff and were given tours of the CAPRISA head office, the CAPRISA eThekweni Research Clinic, and the CAPRISA Vulindlela Research Clinic.

Photo top (L-R): Prof Quarraisha Abdool Karim, Cllr Vusumuzi Cyril Xaba, and Prof Salim Abdool Karim.



Photo bottom: Front row: Delegates from Freya Biosciences, as well as CAPRISA Director, Prof Salim Abdool Karim, CAPRISA Head of Mucosal Immunology Research, Prof Derseree Archary. Back row: CAPRISA Senior Scientist, Dr Sinaye Ngcapu, CAPRISA Research Clinician, Dr Disebo Potloane, and CAPRISA fellows.




A selection of scientific papers published in 2023

- *68 **Naidoo K, Perumal R**, Cox H, Mathema B, Loveday M, Ismail N, Omar SV, Georghiou SB, **Daftary A, O'Donnell M**, Ndjeka N. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis-lessons from the South African experience. *Lancet Infect Dis*. 2024;24(9):e559-e575. doi:10.1016/S1473-3099(24)00144-0.
- 69 Tobin NH, Li F, Brummel S, Flynn PM, Dababhai S, **Moodley D**, Chinula L, Violari A, Fowler MG, Rouzier V, Kuhn L. Maternal HIV infection and the milk microbiome. *Microbiome*. 2024;12(1):182. doi: 10.1186/s40168-024-01843-8.
- 70 Ndembi N, Mekonen TT, Folayan MO, Dereje N, Kruger A, Fokam J, Temfack E, Raji T, Nachega J, Boum Y, Crowell TA, Ngongo AN, Mboup S, Ntoui F, Loots G, Makanga M, Sow S, **Abdool Karim SS**, Nkengasong J. Strengthening and expanding capacities in clinical trials: advancing pandemic prevention, preparedness and response in Africa. *Nature Communications*. 2024;15(1):8662. doi: 10.1038/s41467-024-53126-3.
- 71 Ndembi N, **Abdool Karim SS**. Africa aims to avert an mpox pandemic. *Science*. 2024;386(6717):7. doi: 10.1126/science.adt4793.
- 72 **Perumal R, Naidoo K**. Are We Capable of Unveiling the Missed Epidemic of Isoniazid-resistant Tuberculosis?. *Annals of the American Thoracic Society*. 2024;21(10):1381-2. doi: 10.1513/AnnalsATS.202407-772ED
- 73 Clark A, Topol E, Greely H, **Abdool Karim SS, Abdool Karim Q**, Laxminarayan R. Hopes, fears and uncertainty: life scientists react to Trump's election victory. *Nature*. 2024;635(8040):812-814. doi: 10.1038/d41586-024-03813-4.
- 74 **Mahomed S**, Bukusi E, Sikazwe I, Musoke P, **Abdool Karim Q**. A risk- and needs-based strategy HIV prevention for adolescent girls and young women, WHO African Region. *Bull World Health Organ*. 2024;102(12):913-915. doi: 10.2471/BLT.23.291160.
- 75 **Abdool Karim Q**, Mayer KH, **Mohan J**, Del Rio C. The audacious goal to end AIDS by 2030: aspiration or reality? *Journal of the International AIDS Society*. 2024;27(7):e26339. doi: 10.1002/jia2.26339.
- 76 Bekker LG, Das M, **Abdool Karim Q**, Ahmed K, Batting J, Brumskine W, Gill K, **Harkoo I**, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, **Mansoor LE, Moodley D**, Naicker V, Naidoo L, **Naidoo M**, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, **Potloane D**, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F; PURPOSE 1 Study Team. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. *New England Journal of Medicine*. 2024; 391(13):1179-1192. doi: 10.1056/NEJMoa2407001.
- 77 **Samsunder N, Sivro A, Hassan-Moosa R, Lewis L, Kara Z, Baxter C, Karim QA, Karim SA, Kharsany ABM, Naidoo K, Ngcapu S**. Evaluating diagnostic accuracy of an RT-PCR test for the detection of SARS-CoV-2 in saliva. *Diagnostic and Prognostic Research*. 2024;8(1):9. doi: 10.1186/s41512-024-00176-2.
- 78 Sun K, Bhiman JN, Tempia S, Kleynhans J, Madzorera VS, Mkhize Q, Kaldine H, McMorrow ML, Wolter N, Moyes J, Carrim M, Martinson NA, Kahn K, Lebina L, du Toit JD, Mkhencele T, von Gottberg A, Viboud C, **Moore PL**, Cohen C; PHIRST-C group. SARS-CoV-2 correlates of protection from infection against variants of concern. *Nature Medicine*. 2024;30(10):2805-2812. doi: 10.1038/s41591-024-03131-2.
- 79 **Loveday M**, Gandhi NR, Khan PY, Theron G, Hlangu S, Holloway K, Chotoo S, Singh N, Marais BJ. Critical assessment of infants born to mothers with drug resistant tuberculosis. *EClinicalMedicine*. 2024 Sep 5;76:102821. doi: 10.1016/j.eclinm.2024.102821.

* continuation from previous newsletter

For the complete list of publications see here: <http://bit.ly/3IRvjZd>



Partner Institutions:



Board of Control: B Ntuli (Chair) • M Rajab (Deputy Chair) • Q Abdool Karim • SS Abdool Karim • AC Bawa • JH Beare • JM Frantz • LP Fried (US) • ST Harrison • TL Jones • ARDH Moosa • M Moshabela • K Naidoo • A Nortier • A Puren • HW Sherwin • LV Theron

Scientific Advisory Board: F Barré-Sinoussi (Chair) • T Quinn (Vice Chair) • P Godfrey-Faussett • R Hayes • J Mascola • Y Pillay • S Swaminathan

Registration number: 2002/024027/08 • PBO number: 930 018 155